Condition: Mesothelioma · Mesotheliomas Pleural · Mesothelioma; Pleura · Sponsor: Memorial Sloan Kettering Cancer Center
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
This description comes directly from the study's public registry record.
Michael Offin, MD · 646-608-3763 · offinm@mskcc.org
Robert Daly, MD, MBA · 646-608-3789 · dalyr1@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center @ Commack | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan - Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06477419